Increased procoagulant function of microparticles in pediatric inflammatory bowel disease: Role in increased thrombin generation

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 4, 2013, Pages 401-407

  Deutschmann, Andrea ^a   Schlagenhauf, Axel ^a   Leschnik, Bettina ^a   Hoffmann, Karl Martin ^a   Hauer, Almuthe ^a   Muntean, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Crohn disease; microparticles; ulcerative colitis; venous thromboembolism

Indexed keywords

THROMBIN;

ADOLESCENT; ARTICLE; CALIBRATED AUTOMATED THROMBOGRAPHY; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGICAL PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; ULCERATIVE COLITIS;

ADOLESCENT; AUSTRIA; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CELL-DERIVED MICROPARTICLES; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KINETICS; MALE; PROTHROMBIN; RISK; SEVERITY OF ILLNESS INDEX; THROMBIN; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 84875851667     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31827daf72     Document Type: Article

References (49)

1. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4.
2. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542-8.
3. Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937-43.
4. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996;38:733-7.
5. Novacek G, Vogelsang H, Genser D, et al. Changes in blood rheology caused by Crohn's disease. Eur J Gastroenterol Hepatol 1996;8: 1089-93.
6. van Wersch JW, Houben P, Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990;28:513-7.
7. Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995;7:1183-8.
8. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883-9.
9. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007;102:174-86.
10. Gris JC, Schved JF, Raffanel C, et al. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990; 63:472-5.
11. Saibeni S, Bottasso B, Spina L, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004;99:1966-70.
12. Saibeni S, Saladino V, Chantarangkul V, et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010;125: 278-82.
13. Bernhard H, Deutschmann A, Leschnik B, et al. Thrombin generation in pediatric patients with Crohn's disease. Inflamm Bowel Dis 2011;17: 2333-9.
14. Piccin A, Murphy WG, Smith OP. Circulating microparticles: patho-physiology and clinical implications. Blood Rev 2007;21:157-71.
15. Shet AS. Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag 2008;4:769-74.
16. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 2010;125 (suppl 1):S46-8.
17. VanWijk MJ, VanBavel E, Sturk A, et al. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277-87.
18. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89:1121-32.
19. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phos-pholipid distribution during platelet activation. Biochim Biophys Acta 1983;736:57-66.
20. Morel O, Hugel B, Jesel L, et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004;91:345-53.
21. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101:841-3.
22. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-5.
23. Meziani F, Tesse A, David E, et al. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol 2006;169:1473-83.
24. Sellam J, Proulle V, Jungel A, et al. Increased levels of circulating microparticles in primary Sjogren's syndrome, systemic lupus erythe-matosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 2009;11:R156.
25. Van Aalderen MC, Trappenburg MC, Van Schilfgaarde M, et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost 2011;9:223-6.
26. Pattanapanyasat K, Gonwong S, Chaichompoo P, et al. Activated platelet-derived microparticles in thalassaemia. Br J Haematol 2007; 136:462-71.
27. Chamouard P, Desprez D, Hugel B, et al. Circulating cell-derived microparticles in Crohn's disease. Dig Dis Sci 2005;50:574-80.
28. Andoh A, Tsujikawa T, Hata K, et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005;100:2042-8.
29. Pamuk GE, Vural O, Turgut B, et al. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. Am J Hematol 2006;81:753-9.
30. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21.
31. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
32. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
33. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypo-coagulability. Pathophysiol Haemost Thromb 2002;32:249-53.
34. Ollivier V, Wang J, Manly D, et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res 2010;125:90-6.
35. Sturk-Maquelin KN, Nieuwland R, Romijn FP, et al. Pro-and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003;1:1920-6.
36. Schweintzger S, Schlagenhauf A, Leschnik B, et al. Microparticles in newborn cord blood: slight elevation after normal delivery. Thromb Res 2011;128:62-7.
37. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657-63.
38. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood 1999;94:2169-78.
39. Cvirn G, Gallistl S, Leschnik B, et al. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003;1:263-8.
40. Cvirn G, Gallistl S, Rehak T, et al. Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma. J Thromb Haemost 2003;1:1785-90.
41. Fritsch P, Cvirn G, Cimenti C, et al. Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor. J Thromb Haemost 2006;4:1071-7.
42. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorti-coids on hemostatic factors in healthy volunteers. Thromb Res 2006;118:247-52.
43. Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012;36:312-23.
44. Szotowski B, Antoniak S, Poller W, et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005;96:1233-9.
45. Yoshida H, Yilmaz CE, Granger DN. Role of tumor necrosis factor-alpha in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis 2011;17:2217-23.
46. Yoshida H, Russell J, Senchenkova EY, et al. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 2010;177:2774-81.
47. Meziani F, Tesse A, Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endo-thelium: role in health and diseases. Pharmacol Rep 2008;60: 75-84.
48. Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-95.
49. Sprague DL, Elzey BD, Crist SA, et al. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008;111:5028-36.